Eraxis
Eraxis Brand names, Eraxis Analogs
Eraxis Brand Names Mixture
- No information avaliable
Eraxis Chemical_Formula
C34H36N2O5S
Eraxis RX_link
No information avaliable
Eraxis fda sheet
Eraxis msds (material safety sheet)
Eraxis Synthesis Reference
No information avaliable
Eraxis Molecular Weight
584.726 g/mol
Eraxis Melting Point
No information avaliable
Eraxis H2O Solubility
Insoluble
Eraxis State
Solid
Eraxis LogP
8.369
Eraxis Dosage Forms
Capsules (250 mg)
Eraxis Indication
For combination antiretroviral treatment of HIV-1 infected adult patients with evidence of viral replication, who are highly treatment-experienced or have HIV-1 strains resistant to multiple protease inhibitors.
Eraxis Pharmacology
Tipranavir is a non-peptidic protease inhibitor (PI) of HIV. Protease inhibitors block the part of HIV called protease. HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Nelfinavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles. Protease inhibitors are almost always used in combination with at least two other anti-HIV drugs.
Eraxis Absorption
Absorption is limited, although no absolute quantification of absorption is available.
Eraxis side effects and Toxicity
Oral LD50 in rat is over 5,000 mg/kg. Side effects include thirst and hunger, unexplained weight loss, increased urination, fatigue, and dry, itchy skin.
Eraxis Patient Information
No information avaliable
Eraxis Organisms Affected
Human immunodeficiency virus
